Skip to main content
Premium Trial:

Request an Annual Quote

Seven Bridges Scientific Advisory Board

Seven Bridges has appointed James Knight, Jan Korbel, Charles Lee, Heng Li, Gholson Lyon, and Gokhan Hotamisligil to its newly formed scientific advisory board. Knight is currently the director of bioinformatics and research scientists at The Knight Lab at Yale University. Korbel is the principal investigator and senior scientists at the European Molecular Biology Laboratory in Heidelberg, Germany. Lee is the scientific director and professor at the Jackson Laboratory for Genomic Medicine. Li is a research scientists at the Broad Institute at MIT and Harvard, working with David Reich and David Altshuler to understand the genetic causes of disease. Lyon is the head of Cold Spring Harbor Laboratory's Lyon Lab and a research scientist at the Utah Foundation for Biomedical Research. Hotamisligil is the James S. Simmons professor of genetics and metabolism and chair of the department of genetics and complex diseases at Harvard University's School of Public Health.

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.